Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-Dialysis Dependent Chronic Kidney Disease

Trial Profile

Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-Dialysis Dependent Chronic Kidney Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2014

At a glance

  • Drugs Iron isomaltoside 1000 (Primary)
  • Indications Iron deficiency anaemia
  • Focus Pharmacokinetics
  • Sponsors Pharmacosmos
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top